Wynn Capital LLC Invests $1.98 Million in McKesson Co. (NYSE:MCK)

Wynn Capital LLC purchased a new stake in shares of McKesson Co. (NYSE:MCK - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 4,272 shares of the company's stock, valued at approximately $1,978,000. McKesson makes up about 1.6% of Wynn Capital LLC's investment portfolio, making the stock its 14th biggest position.

Other large investors have also added to or reduced their stakes in the company. Raymond James & Associates grew its holdings in shares of McKesson by 6.1% in the fourth quarter. Raymond James & Associates now owns 153,180 shares of the company's stock worth $70,919,000 after purchasing an additional 8,784 shares during the last quarter. Allspring Global Investments Holdings LLC grew its stake in McKesson by 6.8% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 85,779 shares of the company's stock valued at $39,714,000 after acquiring an additional 5,425 shares during the period. Insight Wealth Strategies LLC purchased a new position in McKesson in the 4th quarter valued at $1,813,000. Aspire Private Capital LLC raised its holdings in shares of McKesson by 3.2% during the 3rd quarter. Aspire Private Capital LLC now owns 1,957 shares of the company's stock worth $851,000 after acquiring an additional 60 shares during the period. Finally, Argus Investors Counsel Inc. purchased a new position in shares of McKesson during the 4th quarter worth $891,000. Hedge funds and other institutional investors own 85.07% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on MCK shares. SVB Leerink initiated coverage on shares of McKesson in a research note on Monday, February 26th. They set an "outperform" rating and a $600.00 target price on the stock. Barclays assumed coverage on McKesson in a research note on Wednesday, January 3rd. They issued an "overweight" rating and a $537.00 price objective on the stock. UBS Group lifted their price objective on McKesson from $575.00 to $620.00 and gave the stock a "buy" rating in a report on Wednesday, March 6th. StockNews.com lowered McKesson from a "strong-buy" rating to a "buy" rating in a research report on Thursday, January 4th. Finally, Morgan Stanley upped their price objective on McKesson from $522.00 to $548.00 and gave the company an "overweight" rating in a report on Monday, April 15th. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $533.50.

Insider Activity

In related news, EVP Leann B. Smith sold 186 shares of McKesson stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $496.00, for a total value of $92,256.00. Following the completion of the transaction, the executive vice president now owns 1,511 shares in the company, valued at $749,456. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other McKesson news, EVP Leann B. Smith sold 186 shares of the company's stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $496.00, for a total value of $92,256.00. Following the transaction, the executive vice president now directly owns 1,511 shares in the company, valued at approximately $749,456. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Brian S. Tyler sold 3,473 shares of the stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $524.55, for a total transaction of $1,821,762.15. Following the sale, the chief executive officer now directly owns 43,445 shares of the company's stock, valued at approximately $22,789,074.75. The disclosure for this sale can be found here. Company insiders own 0.21% of the company's stock.

McKesson Trading Up 0.7 %

MCK stock traded up $3.55 on Wednesday, hitting $535.56. The company had a trading volume of 418,139 shares, compared to its average volume of 687,556. McKesson Co. has a 12-month low of $352.34 and a 12-month high of $543.00. The stock has a market cap of $70.38 billion, a price-to-earnings ratio of 24.10, a P/E/G ratio of 1.43 and a beta of 0.45. The stock's 50-day simple moving average is $526.12 and its 200 day simple moving average is $488.15.

McKesson (NYSE:MCK - Get Free Report) last posted its quarterly earnings results on Wednesday, February 7th. The company reported $7.74 EPS for the quarter, beating the consensus estimate of $7.05 by $0.69. The business had revenue of $80.90 billion during the quarter, compared to analyst estimates of $77.93 billion. McKesson had a net margin of 0.99% and a negative return on equity of 262.63%. The company's quarterly revenue was up 14.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $6.90 EPS. Research analysts forecast that McKesson Co. will post 27.59 earnings per share for the current year.

McKesson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, July 1st. Shareholders of record on Monday, June 3rd will be given a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 0.46%. McKesson's dividend payout ratio is presently 11.24%.

McKesson Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.